Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 9/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | GFER | P55789 | 5/20 | 0.68 |
| ▸ | CASP6 | P55212 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126532 | 0.86 | CYP3A4 (0.74) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL5544806 | 0.85 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL14220699 | 0.85 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL5544811 | 0.85 | L3MBTL1 (0.73) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL2581059 | 0.84 | MAPT (0.75) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL30230124 | 0.84 | MAPT (0.75) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL24518339 | 0.83 | L3MBTL1 (0.71) | L3MBTL1MAPTALDH1A1KMT2AGFER | |
| SCHEMBL31147209 | 0.83 | L3MBTL1 (0.71) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL22054784 | 0.83 | CYP3A4 (0.74) | L3MBTL1MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL13514054 | 0.83 | GFER (0.62) | L3MBTL1MAPTALDH1A1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| WO-2022124748-A1 | PYRAZOLOPYRIMIDINE SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF CANCER-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2022-06-16 | — | — | WO | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-113614087-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10947238-B2 | Wee1 kinase inhibitors and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947238-B2 | Wee1 kinase inhibitors and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2007097697-A1 | THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007097697-A1 | THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947238-B2 | Wee1 kinase inhibitors and methods of making and using the same | WEE1, WEE2, MAP3K15 | L3MBTL1 2316/4885MAPT 2360/4885ALDH1A1 4128/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | L3MBTL1 457/4885MAPT 470/4885ALDH1A1 4333/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | L3MBTL1 644/4885MAPT 634/4885ALDH1A1 4394/4885 |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | WEE1, WEE2, RCE1 | L3MBTL1 4000/4885MAPT 25/4885ALDH1A1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.